A Wiltshire-headquartered healthcare group said that its revenue remained stable over the first six months of the year.
Chippenham’s Alliance Pharma said in the first half of the year revenues were £82.4m compared to £81m 12 months ago.
The first half of the year saw a "mixed performance" with regulatory issues resulting in some manufacturing delays in smaller products. The company included revenue growth for its Kelo-Cote franchise and Nizoral, saying that it was in line with expectations.
Elsewhere Amberen revenues returned to growth in the second quarter on a like-for-like basis, and the group's operating performance remained unchanged.
Read more:
Chief executive Peter Butterfield, who had taken a break from his role, is now back in post.
Mr Butterfield, who has held the position since 2018, was embroiled in an investigation by the º£½ÇÊÓƵ competition watchdog. The Competition and Markets Authority has been investigating alleged anti-competitive practices in relation to the sale of prescription anti-nausea tablets.
In these latest set of results from the company Mr Butterfield said: "I am pleased to be back in the business full time and to be focused on driving the company's growth through the implementation of our long-term strategy. We are encouraged by the recovery in China and the significant market share gains made by Kelo-Cote, along with the excellent progress of Nizoral. Meanwhile our wider portfolio continues to provide a robust platform from which to grow our Consumer Healthcare brands.
"Our free cash flow is expected to continue to build strongly throughout 2023, which we anticipate will reduce our net debt and leverage by the end of the year. The board's expectation for full year operating performance is unchanged."
Like this story? Why not sign up to get the latest South West business news straight to your inbox.
